FDA Decides Retatrutide Is a Drug, Not a Biologic (October 2, 2026)

The retatrutide FDA decision came on October 2, 2026: the agency found that retatrutide is a drug, not a biological product, so any application to approve it would go under section 505 of the Federal Food, Drug, and Cosmetic Act. That's the new drug application route, not the biologics license application Lilly had said it planned. The primary source is the FDA's October 2 letter, filed with the Seventh Circuit on October 8.

This page records the decision and where the case stood on October 31. The drug or biologic page goes through the legal question in depth.

What the FDA letter says

The letter is signed by Janice L. Weiner, Principal Regulatory Counsel in the Office of Regulatory Review at the FDA's drug center (CDER). Its holding, verbatim: retatrutide "is neither a 'protein' nor an 'analogous product' to a 'protein' and is therefore not a biological product." And the consequence: "Accordingly, an application for retatrutide would need to be submitted under section 505 of the Federal Food, Drug, and Cosmetic Act."

It also rejects Lilly's argument that its own recommendation took effect by default under the 60-day rule (21 U.S.C. 360bbb-2(c)). Lilly asked on January 19, 2024 for retatrutide to be regulated "as a biological product under a biologics license application (BLA)," and the FDA answered on March 18, 2024, "within the 60-day window."

How the retatrutide FDA decision fits the court case

October 2 was the FDA redoing the part of its 2024 decision that a federal court had sent back. The dates, from the court record and the FDA letter:

The two briefs pull in opposite directions. The Justice Department argued: "Lilly cannot appeal a district court's order remanding to an agency." Lilly argued the FDA's new decision confirms "that this appeal is the only proceeding that can address the issues presented here."

What it means for approval

For someone waiting on retatrutide, the route matters less than it sounds. Under either one the FDA reviews the same Phase 3 results, and by October 31 Lilly had reported six positive Phase 3 trials. What changes is which application Lilly files and which part of the law governs it.

Our read: the case can still move the filing paperwork around, but nothing in the October 2 letter questions whether retatrutide works or is safe. That question only starts once Lilly files.

What comes next

Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

The next thing to watch is the appeals court's answer on jurisdiction. The FDA approval page covers what a review involves, and the release date page works through when a 2027 filing could reach pharmacies.

What the decision doesn't change

It doesn't make anything legal to sell. The FDA's own page says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." No approved version exists, so anything listed as retatrutide for sale online still isn't Lilly's product.